Anebulo Pharmaceuticals delivered QQ2 2025 results that align with a clinical-stage, pre-revenue biotechnology company. Revenue remained unavailable, with a first-instance net loss of approximately $2.463 million and an EBITDA loss near $2.403 million. Quarterly operating expenses totaled about $2.588 million, comprised of $1.221 million in R&D and $1.368 million in G&A. The company reported no tax expense and a modest interest expense of roughly $59,696, underscoring its non-operating funding dynamics at this stage. Management guidance is not disclosed in the provided filing, reflecting the typical early-stage biotech focus on pipeline advancement rather than near-term revenue generation.
Liquidity was robustly enhanced by financing activities that added $15 million in net cash, backed by a substantial opening cash balance and a positive net change in cash of about $13.59 million for the period. Ending cash stood at approximately $14.999 million. This positions Anebulo with a multi-year runway to pursue ANEB001 development and potential partnership opportunities, albeit with ongoing dilution risk from equity issuances. The company carries a meaningful accumulated deficit and a pre-revenue business model, which will require successful clinical readouts and strategic partnerships to translate into shareholder value.
Looking forward, the key catalysts remain clinical data readouts for ANEB001 and any potential licensing or collaboration agreements to monetize the pipeline. The investment thesis is contingent on continued execution in trials, achieving safety and efficacy milestones, and the ability to secure strategic partnerships or additional financing on favorable terms.
Key Performance Indicators
Operating Income
Increasing
-2.59M
QoQ: -7.30% | YoY: 6.25%
Net Income
Increasing
-2.46M
QoQ: -11.90% | YoY: 9.36%
EPS
Increasing
-0.09
QoQ: -5.77% | YoY: 18.36%
Revenue Trend
Margin Analysis
Financial Highlights
Revenue status: No reported revenue in QQ2 2025 (N/A for YoY/QoQ).
Profitability:
- Operating income: -$2.588 million for QQ2 2025; YoY growth reported as +6.25% and QoQ change of -7.30% in the provided metrics context, underscoring ongoing pre-revenue burn with a fluctuating quarterly expense base.
- Net income: -$2.463 million; YoY change +9.36% and QoQ change -11.90%.
- EBITDA: -$2.403 million; EBITDA margin not meaningful with no revenue in a pre-revenue stage.
- EPS (diluted): -$0.0898; YoY +18.36%, QoQ -5.77%.
Cash flow and liquidity:
- Net cash used in operating activities: -$1.405 million for QQ2 2025 (operating cash flow).
- Working capital items: cash impact components include depreciation & amortization of $3.00, stock-based compensation of $564,333, and working capital movements (e.g., accounts receivable $214,606; accounts payable $29,776; other working capital -$408,512).
- Net cash provided by (used in) financing activities: +$15.0 million (common stock issued: 15,000,000 shares).
- Net change in cash: +$13.594 million; cash balance at period end: $14.999 million; cash balance at beginning: $1.404 million.
Balance sheet:
- Total assets: $15.841 million; total current assets: $15.395 million.
- Total liabilities: $0.879 million; total stockholders’ equity: $14.962 million.
- Cash and cash equivalents: $14.999 million; retained earnings: -$70.068 million; no debt liabilities reported; net debt: -$14.998 million (net cash).
- Dilution indicators: common stock issued of $15.0 million in equity financing; weighted-average shares outstanding: 27.415 million.
Valuation/context:
- Price-to-book: 3.08; enterprise-value multiple: negative (due to net cash balance).
- Price-to-earnings: negative (loss-making period).
- No revenue-related multiples applicable; valuation remains driven by clinical milestones and potential partnerships.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-2.59M
6.25%
-7.30%
Net Income
-2.46M
9.36%
-11.90%
EPS
-0.09
18.36%
-5.77%
Key Financial Ratios
Return on Assets
Weak
-0.16%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.17%
Return on equity suggests inefficient capital allocation
Current Ratio
Strong
17.52
Current ratio indicates excellent liquidity and financial flexibility
P/E Ratio
Negative
-4.67x
Negative earnings make P/E ratio not meaningful
Price to Book
Premium
3.08x
Trading at premium to book value, reflects strong intangibles or growth
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.